Recent Publications and Grants

Engaged in diverse basic, translational and clinical research, our faculty routinely publish in prestigious journals and successfully compete for major grants from national funders.

Recent Publications

Research Grants

  • NIH/NIAID (Morse) HIV/AIDS Clinical Trial Unit. Andrew Talal (Co-Principal Investigator). 12/1/2013-4/1/2028.
  • A Ribozyme Rescue Strategy for Dry Age-Related Macular Degeneration. John Sullivan (Principal Investigator). VA Central Office. $330,000. 1/1/2025-12/1/2027.
  • Exercise Reset for Concussion - Modifying the Buffalo Concussion Protocol for Application in a Military Environment. John Leddy (Principal Investigator). Department of Defense (CDMRP). 1/1/2023-12/1/2027.
  • Modulation of oligodendrocyte development by voltage-operated calcium channels. Pablo Paez (Principal Investigator). National Institute of Neurological Disorders and Stroke (NINDS). $1,993,750. 12/1/2021-11/1/2027.
  • Mab Passive Vaccination against Acinetobacter baumannii. Thomas Russo (Co-Investigator). NIAID/NIH. $485,053. 9/1/2022-8/1/2027.
  • Center for Advanced Technology in Big Data and Health Sciences. Norma Nowak (Principal Investigator). New York State Department of Empire State Development. $9,200,000. 7/1/2017-6/1/2027.
  • Molecular mechanisms of skin immunity to Staphylococcal infection. Lee Ann Garrett-Sinha (Co-Principal Investigator). NIH. $527,503. 7/1/2022-6/1/2027.
  • A translational bioinformatics approach to elucidate and mitigate polypharmacy induced adverse drug reactions. Zackary Falls (Principal Investigator). National Institute on Drug Abuse. $1,046,435. 7/1/2022-6/1/2027.
  • The role of the nociceptor endocytosis in inflammatory pain. Arin Bhattacharjee (Principal Investigator). National Institute of Neurological Disorders & Stroke. $1,907,471. 6/1/2022-5/1/2027.
  • Novel Combination Therapies to Combat Hypermutable Carbapenem-Resistant P. aeruginosa. Mark Sutton (Co-Principal Investigator). NIH, NIAID. $3,850,992. 5/1/2022-4/1/2027.
  • Liposomal Encapsulation Vaccine Design for Pneumococcal Disease in Aged Subjects. Elsa Bou Ghanem (Co-Principal Investigator). NIA. $2,015,365. 8/1/2022-4/1/2027.
  • Novel Combination Therapies to Combat Hypermutable Carbapenem-Resistant P. aeruginosa. Thomas Russo (Co-Investigator). NIAID/NIH. 5/1/2022-4/1/2027.
  • T Regulatory cell responses in Toxoplasma-infected muscle. Elizabeth Wohlfert (Principal Investigator). NIAID/NIH. $2,445,371. 2/1/2022-3/1/2027.
  • A Multicenter Randomized Controlled Trial of Best Available Therapy versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing Multiple Sclerosis, BEAT-MS (Protocol ITN077AI). Bianca Weinstock-Guttman (Principal Investigator). National Institute of Allergy & Infectious Diseases (NIAID), Division of Allergy, Immunology &Transplantation (DAIT) via a subaward. 1/1/2020-12/1/2026.
  • Impacts of Nicotinamide Riboside on functional capacity and muscle physiology in older veterans. Nikhil Satchidanand (Co-Investigator). Veterans Affairs. 1/1/2022-12/1/2026.